Statin-induced myopathy: minimize the risk and manage according to symptoms and creatine kinase levels

Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33(3): 171–87 McKenney JM, Davidson MH, Jacobson TA, et al. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006; 97(8 Suppl. 1): 89–94C Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97(8 Suppl. A): 69–76C Armitage J. The safety of statins in clinical practice. Lancet 2007; 370(9601): 1781–90 Davidson MH, Clark JA, Glass LM, et al. Statin safety: an appraisal from the Adverse Event Reporting System (AERS). Am J Cardiol 2006; 97Suppl. 8A: 32–43C Masters BA, Palmoski MJ, Flint OP, et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131(1): 163–74 Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25(9): 649–63 Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97 Suppl.: 27–31C